BPC-157 & TB-500 (20mg) | High-Concentration Research Blend

DISCLAIMER: For Research Use Only (RUO). Not for human consumption, cosmetic, diagnostic, or clinical use.

Technical Specifications

Total Content: 20mg (10mg BPC-157 + 10mg TB-500)
Appearance: White lyophilized solid (Compressed Cake/Pellet)
Solubility: High stability in Bacteriostatic Water
Storage: -20°C (Freezer) for long-term stability

Product Overview

The High-Concentration 20mg Precision Blend is our most potent research formulation, specifically calibrated for high-throughput research and laboratories conducting extensive, multi-phase experiments.

Unlike standard low-dose formats, this 20mg vial allows researchers to prepare high-molarity stock solutions from a single source. This minimizes handling errors, reduces reconstitution frequency, and ensures absolute consistency across multiple trial phases.

Why Choose the 20mg Format?

Efficiency for Large Protocols: Ideal for long-duration studies requiring multiple substrate applications.
Cost-Effective Scaling: Provides a higher volume of active reagent for laboratories operating on strict budgets.
Dual-Pathway Synergy: Delivers exactly 10mg of BPC-157 (investigated for its influence on the Nitric Oxide system and angiogenic signaling) and 10mg of TB-500 (studied for its role in actin sequestration and cytoskeletal organization).

Chemical Identity & Mechanism

1. BPC-157: The “Angiogenic Primer”

BPC-157 (Pentadecapeptide) acts by modulating the nitric oxide synthase (NOS) pathway.

Mechanism of Action: It activates the VEGF/VEGFR2-Akt-eNOS signaling axis, “priming” tissue for repair by improving blood flow and upregulating early growth response gene 1 (EGR-1).

2. TB-500: The “Structural Mobilizer”

TB-500 is a highly active fragment derived from thymosin beta-4, with a primary role in actin sequestration.

Mechanism of Action: By modulating actin polymerization—specifically the G-actin to F-actin balance—TB-500 enables cells to alter their morphology and migrate toward sites of injury, providing the structural support necessary to complement BPC-157’s repair signaling.

3. The Synergistic Effect

Recent literature reviews published in 2026 propose that these mechanisms are highly complementary. In theory, BPC-157 supports fibroblast viability under stress, while TB-500 promotes rapid fibroblast migration. Together, they are hypothesized to accelerate extracellular matrix (ECM) remodeling.

Chemical Structures

BPC-157 (Pentadecapeptide)

CAS Number: 137525-51-0
Description: A synthetic pentadecapeptide (15 amino acids) derived from human gastric juice (sequence begins Gly-Glu-Pro-Pro-Pro…). Intended for angiogenesis pathway studies.
Reference: PubChem CID 9941957

TB-500 Fragment (Ac-LKKTETQ)

CAS Number: 885340-08-9
Description: An active 7-amino acid sequence associated with actin-binding and actin dynamics research (thymosin beta-4-derived).
Reference: PubChem CID 16132341

Comparative Research Context

Feature	BPC-157 & TB-500 (Blend)	TB-500 (Mono)	BPC-157 (Mono)
Target Pathway	Dual: Angiogenic + Cytoskeletal	Actin Polymerization	VEGF / Nitric Oxide Axis
Complexity	High (Multi-Variable Analysis)	Moderate (Single Variable)	Moderate (Single Variable)
Mechanism Profile	Co-Activation (Synergistic)	Structural Reorganization	Angiogenic Signaling
Analytical Focus	Synergistic Signaling Assays	Cell Migration & Motility	Endothelial Modulation

Why Researchers Source from PROFOUND AMINOS

The Scientific "Wolverine" Synergy: While the “Wolverine Stack” is a popular cultural label for rapid recovery, its scientific rationale is deeply rooted in complementary biological actions. We use co-lyophilization to deliver these distinct mechanisms in a precise, predefined ratio, eliminating mixing variability and manual measurement errors.
USA Cold-Chain Logistics: Both peptides are sensitive to thermal degradation. To combat the risks of international shipping, our inventory is rigorously maintained at −20°C and dispatched exclusively with active cold packs to preserve peptide-chain integrity.
“Triple G” Compliance: As of 2026, we maintain strict federal-compliance standards. We avoid utilizing full pharmaceutical brand names to respect trademark protections, and all referenced mechanistic data is drawn strictly from peer-reviewed literature, including the Journal of Orthopaedic Research.

Regulatory & Compliance Statement

Classification: Research Use Only (RUO). Not for human consumption, cosmetic, diagnostic, or clinical use.

FDA Warning: BPC-157 is classified as a Category 2 Bulk Drug Substance. It is not approved for the treatment of any disease, injury, or inflammation in humans.

WADA Warning: Both BPC-157 and TB-500 are banned by the World Anti-Doping Agency (WADA) under the category of “Peptide Hormones, Growth Factors, Related Substances, and Mimetics.” Athletes are strictly prohibited from using these compounds.

Safe Handling: Always wear nitrile gloves and appropriate PPE. Refer to the Safety Data Sheet (SDS) for CAS 137525-51-0 and 885340-08-9 prior to handling.

Frequently Asked Questions

Q: Why combine BPC-157 and TB-500 in a single blend? A: Complementary action. BPC-157 modulates signaling (NO- and VEGF-associated pathways) to support microenvironmental conditions like perfusion and cellular stress responses. TB-500 influences cytoskeletal mechanics (actin dynamics) to facilitate cell shape change and migration. The blend addresses both the biochemical signaling and structural/migratory processes of tissue-repair biology.

Q: Is TB-500 exactly the same as thymosin beta-4? A: No. Thymosin beta-4 is a full-length 43-amino acid peptide, whereas TB-500 refers to a synthetic fragment (residues 17-23, sequence Ac-LKKTETQ) containing the core actin-interacting motif. Our blend utilizes this active fragment to allow researchers to focus strictly on the functional region.

Q: What are the primary safety and handling precautions? A: Follow standard GLP-aligned laboratory practices. Use appropriate PPE (gloves, eye protection, lab coat). Handle lyophilized material and reconstituted solutions in a controlled setup (e.g., a laminar flow hood) to minimize aerosol generation and contact risk. Dispose of materials in accordance with institutional chemical-safety procedures.

Q: How should this blend be reconstituted for research? A: A sterile, bacteriostatic aqueous diluent (USP-grade) is the standard vehicle. Add the diluent slowly down the interior wall of the vial. Do not shake vigorously. Instead, use gentle swirling to limit foaming and mechanical shear, which can degrade peptide integrity.